Each week, Florida’s Office of Medical Marijuana Use (OMMU), which is part of the state’s Department of Health, releases data on the state’s medical cannabis program, including an active patient count, a qualified physician count, new dispensary approvals and an update for each operator. That data includes the number of dispensaries and the unit sales each week. This is the tenth New Cannabis Ventures monthly update on the Florida medical cannabis market. We also published a newsletter about the state in May, suggesting that readers be careful with Florida. This article is based upon the update that was provided on Friday by the state for the week ending 04/03. Readers who are interested in the data going forward can visit the OMMU update page.

Patient Growth Has Slowed

We last updated on the Florida market in early March, and the annual growth in patient count had fallen to 3.0% after having been 8.4% in late May.  The rate has remained similar to this low level and was 3.4% this past week:

While the number of patients is still increasing, the growth is very low and down substantially from just a few years ago. 907K patients represent 4% of the state’s population. The number of patients was declining ahead of the potential adult-use legalization but has increased slightly recently to a new high:

Some program improvements over the years have helped excite Florida residents about the medical cannabis program, which now has smokable flower and edibles. Then, the post-pandemic population boom aided patient growth. There has been an increase in dispensaries to 713 from 628 a year ago. This is an increase of 13.5%, which is much faster than the medical cannabis patient growth has been at 3.4%.

Unit Growth Remains Strong

In the most recent week, sales of medical cannabis product units with THC increased by 15.2% from a year ago. Smokeable flower units expanded 19.1% from the week ending 04/04/24. Unit volume growths remain higher than the revenue gain and the patient gain. There are more stores, and unit volume is growing.

We shared that Florida revenue was up only 1.4% from a year earlier in April 2024 by the estimate of BDSA. This was a record low. Florida’s growth picked up a bit afterwards, but in March, it fell 0.5%, the first annual decline ever. Patient growth and dispensary growth have led to unit growth, but the total sales have declined.

Florida MSOs Are Weak

We warned readers on May 17th regarding the MSOs that are big in Florida, as investors seemed overly optimistic. The entire cannabis market has cratered since then, and the entire group of MSOs is sharply lower, especially after the defeat of the adult-use ballot initiative last week. All four leaders in Florida have declined substantially though 04/09/25:

The overall market, as measured by the NCV Global Cannabis Stock Index, currently at 4.56, has declined by 57.9% since then as of 04/09, and the NCV American Cannabis Operator Index, which currently has 8 members and closed at 4.87, has dropped 76.5%. 3 of the Florida 4 have dropped by more than both of them.

Investors were disappointed that Florida voters did not pass the adult-use legalization ballot initiative, and they likely will not be happy with a mature medical market that is slowing and  becoming more competitive. Investors should remain careful in our view with the big Florida operators. Though they have fallen substantially, they could fall more as the market deteriorates.

Exclusive article by Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email